- Home
- VIGL vs ADAG Comparison
VIGL vs ADAG Comparison
Compare VIGL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ADAG
- Stock Information
- Founded
- VIGL 2020
- ADAG 2011
- Country
- VIGL United States
- ADAG China
- Employees
- VIGL N/A
- ADAG N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- ADAG Health Care
- Exchange
- VIGL Nasdaq
- ADAG Nasdaq
- Market Cap
- VIGL 95.2M
- ADAG 91.2M
- IPO Year
- VIGL 2022
- ADAG 2021
- Fundamental
- Price
- VIGL $1.70
- ADAG $2.05
- Analyst Decision
- VIGL Buy
- ADAG Strong Buy
- Analyst Count
- VIGL 6
- ADAG 1
- Target Price
- VIGL $16.60
- ADAG $5.00
- AVG Volume (30 Days)
- VIGL 387.1K
- ADAG 88.6K
- Earning Date
- VIGL 11-07-2024
- ADAG 07-25-2024
- Dividend Yield
- VIGL N/A
- ADAG N/A
- EPS Growth
- VIGL N/A
- ADAG N/A
- EPS
- VIGL N/A
- ADAG N/A
- Revenue
- VIGL N/A
- ADAG $815,746.00
- Revenue This Year
- VIGL N/A
- ADAG N/A
- Revenue Next Year
- VIGL N/A
- ADAG $2.70
- P/E Ratio
- VIGL N/A
- ADAG N/A
- Revenue Growth
- VIGL N/A
- ADAG N/A
- 52 Week Low
- VIGL $1.60
- ADAG $1.60
- 52 Week High
- VIGL $6.06
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- VIGL 23.30
- ADAG 43.59
- Support Level
- VIGL $1.60
- ADAG $2.02
- Resistance Level
- VIGL $2.46
- ADAG $2.15
- Average True Range (ATR)
- VIGL 0.16
- ADAG 0.24
- MACD
- VIGL -0.02
- ADAG -0.00
- Stochastic Oscillator
- VIGL 11.63
- ADAG 21.87
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.